Application of Proteome Profiler Antibody Arrays to Find Angiogenetic Predictors in Glioma Paitents.

Taichung Veterans General Hospital

Status: Unknown

Conditions: Glioblastoma Multiforme; Angiogenesis

Treatments: Radiation: Chemoradiation with temozolomide

Study type: Observational

Funder types: Other

Identifiers

NCT03225963

CE15180B

Details and patient eligibility

About

Bevacizumab has become the standard of care of recurrent glioblastoma based on promising clinical trial results with with response rates up to 50% and progression-free survival up to 9 months. In our study, we set to find the serum angiogenesis biomarkers of bevacizumab response.

Full description

Pre-chemoradiation and post-chemoradiation peripheral blood will be obtained to see if there are some angiogenesis biomarker available for prediction of bevacizumab response later.

Enrollment: 60 estimated patients

Sex: All

Ages: 20 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age older than 20 year old.
• Glioblastoma patients who will receive chemoradiation treatment.

Exclusion criteria

• None